Bishal Gyawali

2 months ago | mdedge.com | Bishal Gyawali

The use of surrogate endpoints to predict overall survival in oncology trials has been vigorously debated in the oncology community. In multiple studies, we have shown that the correlation of surrogate endpoints with overall survival has been weak and, in most cases, inadequate. However, others have made arguments against using overall survival as the gold standard endpoint for cancer drug trials.

Mar 20, 2024 | mdedge.com | Bishal Gyawali

Publish date: March 20, 2024 How should we define success in cancer policy — what should the endpoint be? It’s debatable. Is it fewer cancer deaths? Perhaps improved access to therapies or a reduction in disparities? One thing I know with certainty: The number of new cancer drugs approved by the US Food and Drug Administration (FDA) is not and should not be our primary endpoint in and of itself. I’ll go a step further: It is not even a surrogate marker for success.

Mar 19, 2024 | medscape.com | Bishal Gyawali

How should we define success in cancer policy — what should the endpoint be? It's debatable. Is it fewer cancer deaths? Perhaps improved access to therapies or a reduction in disparities? One thing I know with certainty: The number of new cancer drugs approved by the US Food and Drug Administration (FDA) is not and should not be our primary endpoint in and of itself. I'll go a step further: It is not even a surrogate marker for success.

Nov 16, 2023 | jamanetwork.com | Bishal Gyawali |Garth W. Strohbehn

Immunotherapy in Prepatients—Preventing or Promoting a Malignant Transformation? Nivolumab for Patients With High-Risk Oral Leukoplakia Glenn J. Hanna, MD; Alessandro Villa, DDS, PhD; Shuvro P. Nandi, PhD; Ruichao Shi; Anne ONeill; Mofei Liu; Charles T. Quinn; Nathaniel S. Treister, DMD; Herve Y. Sroussi, DMD, PhD; Piamkamon Vacharotayangul, DDS, PhD; Laura A. Goguen, MD; Donald J. Annino Jr, MD, DMD; Eleni M. Rettig, MD; Vickie Y. Jo, MD; Kristine S.

Sep 1, 2023 | bmjoncology.bmj.com | Kristina Jenei |Fabio Y. Moraes |Bishal Gyawali

Getting new auth cookie, if you see this message a lot, tell someone! Globalisation of clinical trials in oncology: a double-edged sword? Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.